Aphidicolin Increases Platinum Sensitivity in Ovarian Cancer Cells
Author Information
Author(s): JM Sargent, AW Elgie, CJ Williamson, CG Taylor
Primary Institution: Haematology Research, Pembury Hospital, Pembury, Kent, UK
Hypothesis
Can aphidicolin enhance the sensitivity of ovarian cancer cells to platinum-based chemotherapy?
Conclusion
Aphidicolin significantly increases the sensitivity of ovarian cancer cells to platinum agents, especially in those that are resistant.
Supporting Evidence
- 79% of comparisons showed increased sensitivity to platinum agents with aphidicolin.
- The median increase in sensitivity was 10-fold overall.
- Aphidicolin had a greater effect in the resistant group, with a median 13.5-fold increase.
- Cells from 22 of 25 patients showed increased cytotoxicity to platinum drugs when combined with aphidicolin.
Takeaway
Aphidicolin helps make cancer cells more sensitive to chemotherapy, which could help treat ovarian cancer better.
Methodology
The study used fresh cells from patients with ovarian adenocarcinoma and measured cell survival after drug exposure using the MTT assay.
Limitations
Not all primary tumors showed increased sensitivity, and the study was conducted in vitro, which may not fully represent clinical outcomes.
Participant Demographics
25 patients with histologically confirmed ovarian adenocarcinoma, including 15 with de novo disease and 10 with recurrence.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website